Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

The article discusses a study which investigated the effect on cerebrospinal fluid (CSF) biomarkers of axonal damage, astrogliosis, and B-cell regulation following immunosuppressive therapy with mitoxantrone or rituximab in progressive multiple sclerosis (PMS). The study included 35 patients with MS, five with primary progressive (PP) MS and 30 with SPMS. The study concluded that some patients with active PMS may have plausible beneficial effects from potent immunosuppressive regimens.